International Clinical Trial: Safety and Feasibility of First-line Avutometinib and Defactinib in Patients With Newly Diagnosed High-grade Gliomas

Geneva, Aug. 31 -- International Clinical Trials Registry received information related to the study (NCT07778602) titled 'Safety and Feasibility of First-line Avutometinib and Defactinib in Patients With Newly Diagnosed High-grade Gliomas' on Aug. 18.

Study Type: Interventional

Study Design: Allocation: Non-Randomized. Intervention model: Sequential Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Condition: MGMT-unmethylated Glioblastoma (GBM) IDH Wildtype Glioblastoma

Intervention: Drug: avutometinib and defactinib for 3 weeks on/1 week off

Recruitment Status: Not recruiting

Phase: Early Phase 1

Date of First Enrollment: November ...